• 1
    Erichsen MM, Lovas K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94:48824890.
  • 2
    Winqvist O, Karlsson FA, Kampe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992; 339:15591562.
  • 3
    Bratland E, Skinningsrud B, Undlien DE, Mozes E, Husebye ES. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94:51175124.
  • 4
    Rottembourg D, Deal C, Lambert M et al. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease. J Autoimmun 2010; 35:309315.
  • 5
    Bratland E, Husebye ES. Cellular immunity and immunopathology in autoimmune Addison's disease. Mol Cell Endocrinol 2011; 336:180189.
  • 6
    James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein–Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:30193026.
  • 7
    Chehadeh W, Weill J, Vantyghem MC et al. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis 2000; 181:19291939.
  • 8
    Antonelli A, Ferri C, Pampana A et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117:1013.
  • 9
    Doyle SE, Schreckhise H, Khuu-Duong K et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44:896906.
  • 10
    Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:6977.
  • 11
    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732738.
  • 12
    Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996; 219:339349.
  • 13
    Coccia EM, Severa M, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34:796805.
  • 14
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227264.
  • 15
    Antonelli A, Ferrari SM, Fallahi P et al. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010; 50:260267.
  • 16
    van Koetsveld PM, Vitale G, de Herder WW et al. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab 2006; 91:45374543.
  • 17
    Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7:18211831.
  • 18
    Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:6368.
  • 19
    Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif 2008; 41:960979.
  • 20
    Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011; 13:R88.
  • 21
    van Baarsen LG, van der Pouw Kraan TC, Kragt JJ et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006; 7:522531.
  • 22
    Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008; 105:1243912444.
  • 23
    Akeno N, Smith EP, Stefan M et al. IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 2011; 186:46934706.
  • 24
    Betterle C, Fabris P, Zanchetta R et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23:11771181.
  • 25
    Fabris P, Betterle C, Floreani A et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340:548.
  • 26
    Wesche B, Jaeckel E, Trautwein C et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48:378383.
  • 27
    Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract 2009; 86:e1921.
  • 28
    Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010; 49:403407.
  • 29
    Krysiak R, Boldys A, Okopien B. Autoimmune polyglandular syndrome type 2 induced by treatment with interferon alpha. Am J Med Sci 2011; 341:504507.
  • 30
    Oshimoto K, Shimizu H, Sato N, Mori M. [A case of Addison's disease which became worse during interferon therapy: insulin secretion under hyposmolarity]. Nihon Naibunpi Gakkai Zasshi 1994; 70:511516.
  • 31
    Tran HA, Song S, Lojewski RJ, Reeves GE. Exacerbation of hepatitis C induced subclinical hypoadrenalism by interferon-alpha2beta: a case report. Cases J 2008; 1:157.
  • 32
    Knost JA, Sherwin S, Abrams P, Oldham RK. Increased steroid dependence after recombinant leucocyte interferon therapy. Lancet 1981; 2:12871288.
  • 33
    Paolo WF, Jr, Nosanchuk JD. Adrenal infections. Int J Infect Dis 2006; 10:343353.
  • 34
    Bratland E, Hellesen A, Husebye ES. Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. Mol Cell Endocrinol 2013; 365:7583.
  • 35
    Bratland E, Bredholt G, Mellgren G, Knappskog PM, Mozes E, Husebye ES. The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: the major autoantigen in autoimmune Addison's disease. J Autoimmun 2009; 33:5867.
  • 36
    Itoh N, Hanafusa T, Miyazaki A et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92:23132322.
  • 37
    Huang H, Li X, Lin L et al. Upregulation of thyroid transcription factor-1 and human leukocyte antigen class I in Hashimoto's disease providing a clinical evidence for possible triggering autoimmune reaction. Eur J Endocrinol 2011; 164:795800.
  • 38
    Arvan P, Pietropaolo M, Ostrov D, Rhodes CJ. Islet autoantigens: structure, function, localization, and regulation. Cold Spring Harbour Perspect Med 2012; 2:a007658.
  • 39
    Rotondi M, Falorni A, De Bellis A et al. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab 2005; 90:23572363.
  • 40
    Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007; 28:492520.
  • 41
    Kanczkowski W, Zacharowski K, Wirth MP, Ehrhart-Bornstein M, Bornstein SR. Differential expression and action of Toll-like receptors in human adrenocortical cells. Mol Cell Endocrinol 2009; 300:5765.
  • 42
    Colucci R, Jimenez RE, Farrar W, Malgor R, Kohn L, Schwartz FL. Coexistence of Cushing syndrome from functional adrenal adenoma and Addison disease from immune-mediated adrenalitis. J Am Osteopath Assoc 2012; 112:374379.
  • 43
    Bornstein SR, Chrousos GP. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999; 84:17291736.
  • 44
    Brain RT, Pugh RC, Dudgeon JA. Adrenal necrosis in generalized herpes simplex. Arch Dis Child 1957; 32:120126.
  • 45
    Hertel NT, Jacobsen BB, Pedersen FK, Heilmann C. Adrenocortical insufficiency associated with Epstein–Barr virus infection in a patient with the Wiskott–Aldrich syndrome. Eur J Pediatr 1987; 146:603604.
  • 46
    Schmitt K, Deutsch J, Tulzer G, Meindi R, Aberle S. Autoimmune hepatitis and adrenal insufficiency in an infant with human herpesvirus-6 infection. Lancet 1996; 348:966.
  • 47
    Guinovart RM, Carrascosa JM, Bielsa I, Rodriguez C, Ferrandiz C. A black tongue in a young woman. Clin Exp Dermatol 2011; 36:429430.
  • 48
    Caskey M, Lefebvre F, Filali-Mouhim A et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011; 208:23572366.
  • 49
    Liu D, Cardozo AK, Darville MI, Eizirik DL. Double-stranded RNA cooperates with interferon-gamma and IL-1 beta to induce both chemokine expression and nuclear factor-kappa B-dependent apoptosis in pancreatic beta-cells: potential mechanisms for viral-induced insulitis and beta-cell death in type 1 diabetes mellitus. Endocrinology 2002; 143:12251234.
  • 50
    Rosenthal FD, Davies MK, Burden AC. Malignant disease presenting as Addison's disease. BMJ 1978; 1:15911592.
  • 51
    Wood MA, Hammer GD. Adrenocortical stem and progenitor cells: unifying model of two proposed origins. Mol Cell Endocrinol 2011; 336:206212.
  • 52
    Ohashi PS, Oehen S, Aichele P et al. Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha. J Immunol 1993; 150:51855194.
  • 53
    Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353360.
  • 54
    Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2:14231427.
  • 55
    Stefan M, Jacobson EM, Huber AK et al. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286:3116831179.
  • 56
    Matkovic U, Pacenti M, Trevisan M, Palu G, Barzon L. Investigation on human adrenocortical cell response to adenovirus and adenoviral vector infection. J Cell Physiol 2009; 220:4557.
  • 57
    Xing Y, Parker CR, Edwards M, Rainey WE. ACTH is a potent regulator of gene expression in human adrenal cells. J Mol Endocrinol 2010; 45:5968.
  • 58
    Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383392.
  • 59
    Qin S, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746754.
  • 60
    Antonelli A, Fallahi P, Rotondi M et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154:651658.
  • 61
    Shimada A, Morimoto J, Kodama K et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001; 24:510515.
  • 62
    Uno S, Imagawa A, Saisho K et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010; 57:991996.
  • 63
    Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86:50085016.